164 related articles for article (PubMed ID: 18455242)
1. C5a is not involved in experimental autoimmune myasthenia gravis pathogenesis.
Qi H; Tüzün E; Allman W; Saini SS; Penabad ZR; Pierangeli S; Christadoss P
J Neuroimmunol; 2008 May; 196(1-2):101-6. PubMed ID: 18455242
[TBL] [Abstract][Full Text] [Related]
2. Genetic deficiency of estrogen receptor alpha fails to influence experimental autoimmune myasthenia gravis pathogenesis.
Qi H; Li J; Allman W; Saini SS; Tüzün E; Wu X; Estes DM; Christadoss P
J Neuroimmunol; 2011 May; 234(1-2):165-7. PubMed ID: 21481948
[TBL] [Abstract][Full Text] [Related]
3. Novel animal models of acetylcholine receptor antibody-related myasthenia gravis.
Tüzün E; Allman W; Ulusoy C; Yang H; Christadoss P
Ann N Y Acad Sci; 2012 Dec; 1274():133-9. PubMed ID: 23252908
[TBL] [Abstract][Full Text] [Related]
4. ICOS is essential for the development of experimental autoimmune myasthenia gravis.
Scott BG; Yang H; Tüzün E; Dong C; Flavell RA; Christadoss P
J Neuroimmunol; 2004 Aug; 153(1-2):16-25. PubMed ID: 15265659
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory IgG receptor FcgammaRIIB fails to inhibit experimental autoimmune myasthenia gravis pathogenesis.
Li J; Tüzün E; Wu XR; Qi HB; Allman W; Saini SS; Christadoss P
J Neuroimmunol; 2008 Feb; 194(1-2):44-53. PubMed ID: 18207575
[TBL] [Abstract][Full Text] [Related]
6. Genetic evidence for the involvement of Fcgamma receptor III in experimental autoimmune myasthenia gravis pathogenesis.
Tüzün E; Saini SS; Yang H; Alagappan D; Higgs S; Christadoss P
J Neuroimmunol; 2006 May; 174(1-2):157-67. PubMed ID: 16527362
[TBL] [Abstract][Full Text] [Related]
7. Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis.
Tüzün E; Saini SS; Morgan BP; Christadoss P
J Neuroimmunol; 2006 Dec; 181(1-2):29-33. PubMed ID: 17056125
[TBL] [Abstract][Full Text] [Related]
8. Ocular myasthenia gravis induced by human acetylcholine receptor ϵ subunit immunization in HLA DR3 transgenic mice.
Wu X; Tuzun E; Saini SS; Wang J; Li J; Aguilera-Aguirre L; Huda R; Christadoss P
Immunol Lett; 2015 Dec; 168(2):306-12. PubMed ID: 26493475
[TBL] [Abstract][Full Text] [Related]
9. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis.
Tüzün E; Scott BG; Goluszko E; Higgs S; Christadoss P
J Immunol; 2003 Oct; 171(7):3847-54. PubMed ID: 14500686
[TBL] [Abstract][Full Text] [Related]
10. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells.
Wang W; Milani M; Ostlie N; Okita D; Agarwal RK; Caspi RR; Conti-Fine BM
J Immunol; 2007 Jun; 178(11):7072-80. PubMed ID: 17513756
[TBL] [Abstract][Full Text] [Related]
11. MuSK induced experimental autoimmune myasthenia gravis does not require IgG1 antibody to MuSK.
Küçükerden M; Huda R; Tüzün E; Yılmaz A; Skriapa L; Trakas N; Strait RT; Finkelman FD; Kabadayı S; Zisimopoulou P; Tzartos S; Christadoss P
J Neuroimmunol; 2016 Jun; 295-296():84-92. PubMed ID: 27235354
[TBL] [Abstract][Full Text] [Related]
12. CD4 costimulation is not required in a novel LPS-enhanced model of myasthenia gravis.
Allman W; Qi H; Saini SS; Li J; Tuzun E; Christadoss P
J Neuroimmunol; 2012 Aug; 249(1-2):1-7. PubMed ID: 22626443
[TBL] [Abstract][Full Text] [Related]
13. Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice.
Ulusoy C; Çavuş F; Yılmaz V; Tüzün E
Immunol Invest; 2017 Jul; 46(5):490-499. PubMed ID: 28375749
[TBL] [Abstract][Full Text] [Related]
14. IgG1 deficiency exacerbates experimental autoimmune myasthenia gravis in BALB/c mice.
Huda R; Strait RT; Tüzün E; Finkelman FD; Christadoss P
J Neuroimmunol; 2015 Apr; 281():68-72. PubMed ID: 25867470
[TBL] [Abstract][Full Text] [Related]
15. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis.
Wang HB; Shi FD; Li H; van der Meide PH; Ljunggren HG; Link H
Clin Immunol; 2000 May; 95(2):156-62. PubMed ID: 10779409
[TBL] [Abstract][Full Text] [Related]
16. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?
Baggi F; Antozzi C; Toscani C; Cordiglieri C
Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):19-30. PubMed ID: 22159475
[TBL] [Abstract][Full Text] [Related]
17. Novel complement inhibitor limits severity of experimentally myasthenia gravis.
Soltys J; Kusner LL; Young A; Richmonds C; Hatala D; Gong B; Shanmugavel V; Kaminski HJ
Ann Neurol; 2009 Jan; 65(1):67-75. PubMed ID: 19194881
[TBL] [Abstract][Full Text] [Related]
18. Animal models of myasthenia gravis.
Christadoss P; Poussin M; Deng C
Clin Immunol; 2000 Feb; 94(2):75-87. PubMed ID: 10637092
[TBL] [Abstract][Full Text] [Related]
19. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production.
Deng C; Goluszko E; Tüzün E; Yang H; Christadoss P
J Immunol; 2002 Jul; 169(2):1077-83. PubMed ID: 12097416
[TBL] [Abstract][Full Text] [Related]
20. Complement associated pathogenic mechanisms in myasthenia gravis.
Tüzün E; Christadoss P
Autoimmun Rev; 2013 Jul; 12(9):904-11. PubMed ID: 23537510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
